Sorry to keep banging on about this,
but I went to the SR users forum yesterday, and it is quite clear that nothing 
is safe.

Although "Diamond operations and commissioning" & "ESRF upgrades" are in the 
high-priority category, the expanded PALS prioritisation document includes this 
in the discussion of  Diamond Phase I:
"...redeploying resources where possible to

ensure that all Phase I beam-lines are operational"


and the ESRF upgrade:

"in the current financial climate even those facilities considered to be a high

priority may not receive all of the funding that they desire"



You don't have to be as cynical as me to see the underlying threat in these.



The development of Diamond -(Phases II and III) is in the medium-priority 
category. Should phases II and III be cut, then Diamond will be effectively 
frozen in its present state. That means no more beam-lines and no development 
of the current ones.

Please respond to the consultation document, note the example of the 
well-orgainsed astronomy lobby and exploit any contact you have with the media 
to emphasise the importance of these facilities in basic  biomedical science 
etc., lobby your MP, etc. etc. as soon as possible.


Peter


PS Overseas subsribers, sorry to fill up you mailboxes, please note that he 
consultaion process will accept comment from outside the UK as well, should you 
feel able to support us.

Peter Moody
1/56 Henry Wellcome Laboratories
University of Leicester
Lancaster Road
Leicester
LE1 9HN
UK
tel. (0)116 229 7097
fax. (0)116 229 7084
________________________________
From: CCP4 bulletin board [EMAIL PROTECTED] On Behalf Of Moody, Dr P.C.E. 
[EMAIL PROTECTED]
Sent: 06 March 2008 17:49
To: [email protected]
Subject: [ccp4bb] STFC Consultation exercise on programmatic review

Following my earlier email, please note that further information has just been 
added to the site (http://www.scitech.ac.uk/stfcconsultation/comment.aspx). 
This includes a brief explanation about what was considered under each heading 
on the PALS prioritisation list.

Peter

Peter Moody
1/56 Henry Wellcome Laboratories
University of Leicester
Lancaster Road
Leicester
LE1 9HN
UK
tel. (0)116 229 7097
fax. (0)116 229 7084

Reply via email to